Ergoteles’s Affimed AFMD Stock Holding History

Ergoteles’s Portfolio AFMD Stock Details AFMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-14,130	Closed	-$84.5K	–	45
2023 Q2	$84.5K	Buy	+14,130	New	+$113K	﹤0.01%	927
2023 Q1	–	Sell	-9,639	Closed	-$120K	–	1203
2022 Q4	$120K	Sell	9,639 -7,259	-43%	-$127K	﹤0.01%	1190
2022 Q3	$348K	Buy	+16,898	New	+$470K	0.01%	912
2022 Q2	–	Sell	-7,850	Closed	-$343K	–	1605
2022 Q1	$343K	Buy	+7,850	New	+$341K	0.01%	798

Other funds holding AFMD

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPSPJS

General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ergoteles's AFMD Position: Q3 2023 in Review

Ergoteles sold out of Affimed (AFMD) in Q3 2023, closing a stake of 14,130 shares — an estimated $84.5K sold.

Ergoteles first reported a position in AFMD in Q1 2022 and held it in 4 quarters. The position peaked at $348K in Q3 2022. 61 funds tracked by Wall St. Rank hold AFMD as of Q3 2023.

Ergoteles reported no remaining Affimed position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 14,130 Affimed shares in Q3 2023, an estimated $84.5K.
Ergoteles first reported a position in Affimed in Q1 2022 and held it in 4 quarters.
Ergoteles's Affimed position peaked at $348K in Q3 2022.
61 funds tracked by Wall St. Rank held Affimed as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.